COMMUNICATION:
A Requirement for the Mitogen-activated Protein Kinase Cascade in Hippocampal Long Term Potentiation*

(Received for publication, March 21, 1997, and in revised form, May 5, 1997)

Joey D. English and J. David Sweatt Dagger

From the Division of Neuroscience, Baylor College of Medicine, Houston, Texas 77030

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

The mitogen-activated protein kinase (MAPK) cascade has been intensely studied as a primary biochemical pathway through which a variety of extracellular stimuli initiate and regulate processes of cellular transformation. That MAPKs are abundantly expressed in postmitotic neurons, however, suggests different yet currently unknown functions for this cascade in the mature nervous system. Here we report that the MAPK cascade is required for hippocampal long term potentiation (LTP), a robust and widely studied form of synaptic plasticity. We observed that PD 098059, a selective inhibitor of the MAPK cascade, blocked MAPK activation in response to direct stimulation of the NMDA receptor as well as to LTP-inducing stimuli. Furthermore, inhibition of the MAPK cascade markedly attenuated the induction of LTP. PD 098059, however, had no effect on the expression of established LTP, and the MAPK cascade was not persistently activated during LTP expression. Our observations provide the first demonstration of a role for the MAPK cascade in the activity-dependent modification of synaptic connections between neurons in the adult mammalian nervous system.


INTRODUCTION

The mitogen-activated protein kinase (MAPK)1 cascade has been classically studied as a critical biochemical pathway involved in cellular transformation events such as cell proliferation and determination. Such work has delineated a pathway by which growth factor receptor activation initiates a complex cascade leading to the activation of Ras, Raf, and MEK, a dual-specific kinase that activates MAPKs via phosphorylations on both threonine and tyrosine residues (reviewed in Refs. 1 and 2).

Although this cascade is typically studied in the context of mitotic cell regulation, its components are actually most abundantly expressed in postmitotic neurons of the developed nervous system (3, 4). At present, however, little is known about the physiologic roles of this cascade in mature neurons. We have begun to investigate the possible involvement of the MAPK cascade in the activity-dependent modulation of synaptic connections between neurons, a putative mechanism for the neuronal basis of learning and memory. In particular, we have examined the role of the MAPK cascade in hippocampal long term potentiation (LTP), a widely studied form of synaptic plasticity (reviewed in Refs. 5 and 6).

Recently, we reported that p42 MAPK (extracellular signal-regulated kinase 2) is activated during the induction of LTP in area CA1 of the hippocampus (7). Though this observation identifies the MAPK cascade as a potential component of the LTP induction cascades in area CA1, the physiologic necessity of MAPK activation during LTP induction remains to be established. To address this question, we have utilized the compound PD 098059 (8, 9), a recently described inhibitor of MEK, to block activation of the MAPK cascade during the delivery of LTP-inducing stimuli. Here we report that inhibition of the MAPK cascade greatly attenuates the induction but not expression of LTP in area CA1. Our observations provide an initial insight into a physiological role for the MAPK cascade in postmitotic neurons in the adult mammalian nervous system: the activity-dependent regulation of synaptic strength.


EXPERIMENTAL PROCEDURES

For hippocampal slice preparation, pharmacology, and electrophysiology, transverse hippocampal slices (400 µm) from 4-8 week old male Sprague-Dawley rats were prepared and maintained as described (7). Drug application, area CA1 subregion microdissection, tissue sonication, fractionation of soluble extracts, Western blotting, and densitometric analysis of phosphotyrosine immunoreactivity were conducted as described previously (7). All data are expressed as means ± S.E. In the present studies, we also utilized an antibody that selectively recognizes tyrosine phosphorylated extracellular signal-regulated kinases (New England Biolabs).

PD 098059 was dissolved in Me2SO and diluted into artificial cerebrospinal fluid (ACSF; in mM 125 NaCl, 2.5 KCl, 1.25 NaH2PO4, 25 NaHCO3, 10 D-glucose, 2 CaCl2, 2 MgCl2, saturated with 95% O2/5% CO2) to give the desired final concentration (with a final Me2SO concentration of 0.33%). For drug application (either PD 098059 or 0.33% Me2SO alone), ACSF solutions were maintained in a 32 °C water bath (to assure the complete solubility of PD 098059). For biochemical analysis of the effect of PD 098059 upon p42 MAPK activation, slices were preincubated in 50 µM PD 098059 or 0.33% Me2SO for 45 min to 1 h prior to NMDA application (100 µM, 4') or HFS (strong induction paradigm, see below). 0.33% Me2SO alone had no effect on NMDA- or HFS-mediated p42 MAPK activation (not shown).

For extracellular field recordings of the Schaffer collateral synapses in area CA1, stimulus intensity was adjusted to elicit a population excitatory postsynaptic potential (pEPSP) that was approximately 25% of the maximum response (initial slope typically about 1 mV/ms), and responses (obtained at 0.05 Hz) were monitored for at least 15 min to ensure a stable base line. Two LTP induction paradigms were employed: 1) modest: two trains of 1-s, 100-Hz stimulation at the test stimulus intensity, with an intertrain interval of 20 s; and 2) strong: three sets of tetani, each set spaced 10 min apart and consisting of two trains of 1-s, 100-Hz stimulation at a stimulus intensity that generated 75% of the maximal pEPSP, with an intertrain interval of 20 s. PD 098059 or 0.33% Me2SO was applied for 1 h prior to tetanization and was maintained throughout the recording period. In initial experiments testing the effect of PD 098095 on LTP elicited with the strong induction protocol, 30-ml solutions of normal ACSF, 0.33% Me2SO, or 100 µM PD 098059 were prepared and recycled through the recording chambers. Similar results were also obtained using 50 µM PD 098059 (which, as with all other experiments, was not recycled), and these data were pooled as noted. For control experiments illustrated in Fig. 3B, an NMDA receptor-mediated pEPSP was isolated by perfusing the slices with a modified ACSF (as described, with the following exceptions: 4 mM CaCl2, 0 mM MgCl2, and 20 µM 6-cyano-7-nitroquinoxaline-2,3-dione).


Fig. 3. PD 098059 does not affect basal synaptic transmission, NMDA receptor-mediated transmission, or HFS-mediated depolarization in area CA1. A, basal synaptic transmission. Following a period of base-line recordings (t = -20 to 0 min), 50 µM PD 098059 was applied for 2.5 h (at t = 0 min, solid horizontal bar). A shows pooled data of four 1-h applications and three 2.5-h applications. Inset, representative traces for base-line transmission (a) and responses following a 2.5 h PD 098059 application (b). B, NMDA receptor-mediated transmission. Average amplitude of the NMDA receptor-mediated pEPSP, normalized to the average base-line response before PD 098059 application (representative experiment). Following a period of base-line recordings (t = -20 to 0 min), 100 µM PD 098059 was applied for >2 h without effect. 50 µM D,L-APV completely and reversibly blocked the pEPSP (t = 60-90 min). Inset, representative pEPSP traces for responses prior to PD 098059 application (a), following 1 h of PD 098059 application (b), and following application of D,L-APV (c). CNQX, 6-cyano-7-nitroquinoxaline-2,3-dione. C, Left, average HFS depolarization responses (normalized to control, CTL). Integral (total depolarization) and steady-state depolarization (SS Depol, average over last 50 ms) during the initial tetanus for control, Me2SO (DMSO)- and PD 098059-treated slices (modest induction protocol). Right, representative HFS-mediated depolarization responses. Scale bars, 2 mV and 90 ms.
[View Larger Version of this Image (33K GIF file)]


RESULTS

PD 098059 Blocks p42 MAPK Activation in Area CA1

To test the physiologic significance of MAPK activation during LTP induction, we employed a recently described inhibitor of MEK, the dual-specific protein kinase responsible for phosphorylating and activating MAPKs. We first determined whether this MEK inhibitor, PD 098059, blocks MAPK activation in area CA1 of the hippocampus. PD 098059 completely abolished basal p42 MAPK phosphotyrosine immunoreactivity as well as the NMDA- and HFS-mediated increase in p42 MAPK tyrosine phosphorylation (Fig. 1A, APT Western). Similar results were obtained using an antibody that selectively recognizes phosphorylated, activated MAPKs (Fig. 1A, alpha -PMAPK Western).


Fig. 1. PD 098059 blocks p42 MAPK activation in area CA1. A, representative anti-MAPK (alpha -MAPK), APT, and anti-phospho-MAPK (alpha -PMAPK) Western blots of soluble extracts from individual area CA1 subregions. Left panels, control (CTL) and NMDA-treated (NMDA) slices pretreated with either Me2SO (drug vehicle) or PD 098059. Right panels, control (CTL) and tetanized (HFS) slices pretreated with either Me2SO (DMSO) or PD 098059. B, normalized p42 MAPK phosphotyrosine immunoreactivity (% of Me2SO-treated control slices). C, control; N, NMDA. Analysis of variance comparisons: Me2SO/NMDA versus Me2SO alone (p < 0.001); PD 098059 alone versus Me2SO alone (p < 0.001); PD 098059 alone versus PD 098059/NMDA (not different). Me2SO/HFS versus Me2SO (p < 0.001); PD 098059 alone versus Me2SO alone (p < 0.001); PD 098059 alone versus PD 098059/HFS (not different).
[View Larger Version of this Image (46K GIF file)]

Quantitative analysis of p42 MAPK APT immunoreactivity is shown in Fig. 1B. Application of either NMDA or HFS led to a significant increase in p42 MAPK phosphotyrosine immunoreactivity (NMDA application: Me2SO alone, 100 ± 13; n = 8; Me2SO/NMDA, 290 ± 38; n = 10 (p < 0.01, Student's t test); HFS application: Me2SO alone, 100 ± 13; n = 6; Me2SO/HFS, 159 ± 20; n = 6; (p < 0.05, Student's t test)). In the presence of the MEK inhibitor PD 098059, however, essentially all phosphotyrosine immunoreactivity (basal as well as the NMDA- and HFS-mediated increases) was eliminated (NMDA application: PD 098059 alone, 6 ± 12; n = 7; PD 098059/NMDA, 16 ± 6; n = 9; HFS application: PD 098059 alone, 9 ± 3; n = 3; PD 098059/HFS, 9 ± 3; n = 3). Together, these data demonstrate that NMDA receptor stimulation or LTP-inducing HFS elicits p42 MAPK activation in area CA1 and that PD 098059 blocks this activation.

PD 098059 Markedly Attenuates the Induction of LTP in Area CA1

Having established that PD 098059 blocks MAPK activation in area CA1, we next determined the effect of this inhibitor on LTP induction. LTP observed in control slices was not significantly different at any time point from LTP observed in slices treated with the drug vehicle, 0.33% Me2SO (pEPSP slope at t = 90 min, control: 173 ± 9%, n = 6; 0.33% Me2SO: 174 ± 11%, n = 4). Overall, stable LTP was elicited in nine of ten control slices, with the initial slope of the pEPSP potentiated to 173 ± 7% of pre-tetanus levels, 90 min following the tetanus (n = 10; Fig. 2A, closed circles). In slices treated with 50 µM PD 098059, however, a decaying potentiation was observed in six of six slices; at t = 90 min, the pEPSP slope was 116 ± 7% of base-line responses (Fig. 2A, open circles). Responses in PD 098059-treated slices were significantly different from control responses for each time point from t = 20 to 90 min (time 0-18 min, p > 0.05; 20-46 min, p < 0.05; 48-90 min, p < 0.01.) These data suggest that the MAPK cascade is critical for the induction of stable LTP in hippocampal area CA1.


Fig. 2. PD 098059 markedly attenuates the induction of LTP in area CA1. Average initial slope of the pEPSP, normalized to the average base-line response before tetanization, plotted over time. A, modest induction protocol. PD 098059 prevented the induction of stable LTP in six of six slices. Control (bullet , n = 10); 50 µM PD 098059 (open circle , n = 6). Inset, representative traces before and 90 min following tetanization in control slices and slices treated with PD 098059. B, strong induction protocol. PD 098059 prevented the induction of stable LTP in nine of ten slices. Control (bullet , n = 9); PD 098059 (open circle , n = 10). Inset, representative traces for average base-line responses and responses taken 60 min after the final tetanization in control slices and slices treated with PD 098059. Scale bars in this and subsequent figures are 2 mV and 3 ms except as noted.
[View Larger Version of this Image (22K GIF file)]

The Effect of PD 098059 upon LTP Induction Is Not Overcome with a Stronger Induction Protocol

In our initial studies, we employed a modest LTP-inducing paradigm consisting of a single set of tetani. The inhibition of certain enzymes (e.g. nitric-oxide synthase (10, 11), fyn kinase knockout mice (12)) blocks LTP induced with similar modest paradigms but not LTP induced with stronger paradigms (e.g. multiple sets of tetani), suggesting a modulatory rather than an obligatory function in LTP induction. To begin to determine whether MAPK activation plays an obligatory or modulatory role in LTP induction, we examined the effect of PD 098059 on LTP elicited with a strong induction protocol: multiple sets of tetani. PD 098059 also markedly attenuated the magnitude of LTP induced with this stronger induction protocol. In control slices, stable LTP was elicited in nine of nine slices, with the initial slope of the pEPSP potentiated to 226 ± 12% of pre-tetanus levels, 60 min following the final tetanus (n = 9; Fig. 2B, closed circles). These data are pooled averages of six control slices and three drug vehicle-treated slices (pEPSP at t = 60 min, control: 228 ± 7%, n = 6; 0.33% Me2SO: 224 ± 38%, n = 3). In slices treated with PD 098059, a decaying potentiation was observed in nine of ten slices; at t = 60 min, the pEPSP slope was 132 ± 13% of base-line responses (n = 10). These data are pooled averages of seven slices treated with 100 µM PD 098059 and three slices treated with 50 µM PD 098059 (100 µM: blocked in six of seven slices; pEPSP slope at t = 60 min, 132 ± 19%; 50 µM: blocked in three of three slices; pEPSP slope at t = 60 min, 132 ± 7%; these data were not significantly different and were thus combined). Responses in PD 098059-treated slices were significantly different from control slices for all time points from 2 to 60 min (p < 0.01 for each). That the effect of PD 098059 is similar on LTP elicited with both modest and strong stimuli (i.e. normal initial responses followed by a slowly decaying potentiation) suggests that the MAPK cascade is an obligatory component of the biochemical induction cascades that subserve this form of synaptic potentiation.

PD 098059 Does Not Affect Basal Synaptic Transmission, NMDA Receptor-mediated Transmission, or HFS-mediated Depolarization

In control experiments, we found that prolonged application of PD 098059 had no effect upon basal synaptic transmission (Fig. 3A). Following 2.5 h of PD 098059 application (50 µM), average initial slope of the pEPSP were 87 ± 10% of base-line responses (n = 3, not significant). Similar results were also obtained with 100 µM PD 098059 applied for 1 h (not shown).

Similarly, PD 098059 had no effect upon NMDA receptor-mediated pEPSPs elicited in the presence of 6-cyano-7-nitroquinoxaline-2,3-dione, an antagonist of non-NMDA receptor subtypes of glutamate receptors (Fig. 3B). NMDA receptor-mediated responses following 1 h of 100 µM PD 098059 application were not different from base-line levels (amplitude: 99 ± 2% of base line; initial slope: 94 ± 4% of base line; n = 3; p > 0.05 for each). Application of a competitive antagonist of the NMDA receptor, D,L-2-amino-5-phosphonovalerate (D,L-APV, 50 µM), completely and reversibly blocked the pEPSP.

Finally, PD 098059 did not alter the depolarization responses to high frequency stimulation (Fig. 3C). No differences were observed for either the total depolarization (integral over entire HFS response) or the steady-state depolarization (average over last 50 ms) observed during the initial tetanus for control, Me2SO- and PD 098059-treated slices (Integral: (control: 100 ± 6.5%, n = 6; Me2SO: 88 ± 12%, n = 4; PD 098059: 100.5 ± 13.5%, n = 6). Steady-state depolarization: (control: 100 ± 7.8%, n = 6; Me2SO: 88 ± 14%, n = 4; PD 098059: 97.4 ± 11.7%, n = 6)). Overall, these results demonstrate that PD 098059 does not affect basal synaptic transmission, NMDA receptor-mediated responses, or HFS-mediated depolarization.

PD 098059 Does Not Affect Protein Kinase C, Protein Kinase A, or Calcium/Calmodulin-dependent Protein Kinase II

Previous reports have demonstrated that PD 098059 shows a high degree of selectivity for MEK, because 50 µM PD 098059 did not alter the activity of over 20 protein kinases, including serine/threonine kinases such as PKC, PKA, c-Raf, and c-Jun N-terminal kinase and tyrosine kinases such as the epidermal growth factor receptor (8, 9). We replicated and extended these observations by testing the effect of PD 098059 on the activity in vitro of three kinases required for LTP induction: PKA, PKC, and CaMKII. PD 098059 (used at concentrations ranging from 1 to 300 µM) did not affect the activity of these protein kinases (data not shown), suggesting that PD 098059 does not attenuate LTP induction by inhibiting any of these three protein kinases previously implicated in LTP induction.

The MAPK Cascade Is Not Persistently Activated during LTP Expression

Ongoing kinase activity is thought to underlie LTP expression (13, 14), and both PKC and CaMKII are persistently activated during LTP expression (15-17). To determine whether ongoing MEK activation is required for LTP expression, we examined the effect of PD 098059 on established LTP in area CA1. In these experiments, stable LTP was elicited in six of six slices using the modest induction protocol, and PD 098059 was applied for 1 h beginning 30 min after tetanization. PD 098059 had no effect on LTP expression (Fig. 4A). Consistent with these observations, PD 098059 also had no effect upon the expression of LTP elicited with the stronger induction paradigm (not shown). Note that a 1-h application of PD 098059 is sufficient for complete reversal of basal p42 MAPK tyrosine phosphorylation (Fig. 1). These results suggest that ongoing activation of the MAPK cascade is not necessary for LTP expression.


Fig. 4. The MAPK cascade is not persistently activated during LTP expression. A, PD 098059 does not affect the expression of established LTP. Average initial slope of the pEPSP, normalized to the average response before tetanization. Stable LTP was induced in six of six slices, and 50 µM PD 098059 was applied for 1 h starting 30 min following tetanization (at t = 30 min, solid horizontal bar). Inset, representative traces for base-line transmission (a), responses 30 min following tetanization (last time point before drug application) (b), and responses 90 min following tetanization (i.e. after one h of PD 098059 application) (c). B, p42 MAPK is not persistently activated during LTP expression. Representative anti-MAPK (alpha -MAPK), APT, and anti-phospho-MAPK (alpha -PMAPK) Western blots of soluble extracts from individual area CA1 subregions from control (CTL) and 45' LTP slices. C, normalized p42 MAPK phosphotyrosine immunoreactivity from control (CTL) and 45' LTP slices (n = 6; not significantly different).
[View Larger Version of this Image (31K GIF file)]

One important caveat to this conclusion, however, is that MAPKs, like PKC and CaMKII, can be persistently activated via phosphorylations (18). Because MEK inhibition would have no effect on persistently activated MAPKs, it remains a possibility that persistently activated MAPKs contribute to LTP expression. We tested this hypothesis by examining p42 MAPK activation levels during LTP expression. No difference in either phosphotyrosine or phospho-MAPK immunoreactivity for p42 MAPK was observed between control and LTP samples taken 45 min following delivery of the strong HFS paradigm, indicating that p42 MAPK is not persistently activated during LTP expression (Fig. 4, B and C; normalized p42 MAPK phosphotyrosine immunoreactivity: 114 ± 20% of control; n = 6; not significant).


DISCUSSION

The abundant expression of MAPKs in mature neurons of the developed nervous system suggests a specialized function for the MAPK cascade in these postmitotic cells. At present, however, little is known regarding either the regulatory mechanisms or physiologic roles of MAPKs in neurons. Using both electrophysiology and biochemistry, we have found that the MAPK cascade is involved in the activity-dependent modulation of synaptic strength, the leading candidate for the neuronal basis of information storage. In particular, we have identified p42 MAPK as a critical component of the biochemical cascades that underlie the induction of hippocampal long term potentiation.

Finally, it is well established that important early events in LTP induction include NMDA receptor stimulation, subsequent postsynaptic calcium influx, and the initiation of several protein kinase cascades. MAPKs appear to be localized in both presynaptic and postsynaptic structures (4, 19) and are thus well positioned to participate in these early events. Interestingly, consideration of several MAPK substrates suggest possible functions of MAPKs in these induction cascades: generation of putative retrograde messengers (e.g. cytosolic phospholipase A2 and the formation of arachadonic acid/platelet-activating factor) (20-22), synaptic vesicle regulation (e.g. synapsin) (19, 23), cytoskeletal modulation (e.g. MAP2 protein) (24), and regulation of gene expression (e.g. transcription factors such as Elk-1) (reviewed in Ref. 25), and CREB (26). In short, the necessity of MAPK activation for LTP induction and the known localization of MAPKs in postmitotic neurons strongly suggest that MAPKs play a critical role in LTP induction cascades. An important step in understanding the function of MAPKs in the strengthening of synaptic connections will be the determination of which MAPK substrates are utilized during LTP.


FOOTNOTES

*   This work was supported by National Institutes of Health Grant MH57014.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    To whom correspondence should be addressed: Div. of Neuroscience, S611, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030. Tel.: 713-798-3107; Fax: 713-798-3946; E-mail: david{at}ligand.neusc.bcm.tmc.edu.
1   The abbreviations used are: MAPK, mitogen-activated protein kinase; LTP, long term potentiation; NMDA, N-methyl-D-aspartate; PKC, protein kinase C; PKA, protein kinase A; CaMKII, calcium/calmodulin-dependent protein kinase II; pEPSP, population excitatory postsynaptic potential; ACSF, artificial cerebrospinal fluid; HFS, high frequency stimulation; APT, anti-phosphotyrosine; D,LAPV, D,L-2-amino-5-phosphonovalerate; MEK, MAPK/ERK kinase; CREB, cAMP response element binding protein.

ACKNOWLEDGEMENTS

We thank Dr. Alan Saltiel for generously providing PD 098059 for these studies and Erik Roberson, Coleen Atkins, and Anne Anderson for critical readings of the manuscript. We also thank Richard Dickason, David Leopold, William J. Martin, and Mark Jacobs for useful discussions.


REFERENCES

  1. Seger, R., and Krebs, E. G. (1995) FASEB J. 9, 726-735 [Abstract/Free Full Text]
  2. Davis, R. J. (1993) J. Biol. Chem. 268, 14553-14556 [Free Full Text]
  3. Boulton, T. G., Nye, S. H., Robbins, D. J., Ip, N. Y., Radziejewska, E., Morgenbesser, S. D., DePinho, R. A., Panayotatos, N., Cobb, M. H., and Yancopoulos, G. D. (1991) Cell 65, 663-675 [Medline] [Order article via Infotrieve]
  4. Fiore, R. S., Bayer, V. E., Pelech, S. L., Posada, J., Cooper, J. A., and Baraban, J. M. (1993) Neuroscience 55, 463-472 [CrossRef][Medline] [Order article via Infotrieve]
  5. Bliss, T. V. P., and Collingridge, G. L. (1993) Nature 361, 31-39 [CrossRef][Medline] [Order article via Infotrieve]
  6. Roberson, E. D., English, J. D., and Sweatt, J. D. (1996) Learn. Mem. 3, 1-24 [Abstract]
  7. English, J. D., and Sweatt, J. D. (1996) J. Biol. Chem. 271, 24329-24332 [Abstract/Free Full Text]
  8. Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., and Saltiel, A. R. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 7686-7689 [Abstract]
  9. Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., and Saltiel, A. R. (1995) J. Biol. Chem. 270, 27489-27494 [Abstract/Free Full Text]
  10. Chetkovich, D. M., Klann, E., and Sweatt, J. D. (1993) Neuroreport 4, 919-922 [Medline] [Order article via Infotrieve]
  11. Haley, J. E., Malen, P. L., and Chapman, P. F. (1993) Neurosci. Lett. 160, 85-88 [Medline] [Order article via Infotrieve]
  12. Grant, S. G. N., O'Dell, T. J., Karl, K. A., Stein, P. L., Soriano, P., and Kandel, E. R. (1992) Science 258, 1903-1910 [Medline] [Order article via Infotrieve]
  13. Malinow, R., Madison, D. V., and Tsien, R. W. (1988) Nature 335, 820-824 [CrossRef][Medline] [Order article via Infotrieve]
  14. Wang, J. H., and Feng, D. P. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 2576-2580 [Abstract]
  15. Klann, E., Chen, S.-J., and Sweatt, J. D. (1991) J. Biol. Chem. 266, 24253-24256 [Abstract/Free Full Text]
  16. Klann, E., Chen, S.-J., and Sweatt, J. D. (1993) Proc. Natl. Acad. Sci. U. S. A 90, 8337-8341 [Abstract/Free Full Text]
  17. Fukunaga, K., Stoppini, L., Miyamoto, E., and Muller, D. (1993) J. Biol. Chem. 268, 7863-7867 [Abstract/Free Full Text]
  18. Murphy, T. H., Blatter, L. A., Bhat, R. V., Fiore, R. S., Wier, W. G., and Baraban, J. M. (1994) J. Neurosci. 14, 1320-1331 [Abstract]
  19. Jovanovic, J. N., Benfenati, F., Siow, Y. L., Sihra, T. S., Sanghera, J. S., Pelech, S. L., Greengard, P., and Czernik, A. J. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 3679-3683 [Abstract/Free Full Text]
  20. Lin, L.-L., Wartmann, M., Lin, A. Y., Knopf, J. L., Seth, A., and Davis, R. J. (1993) Cell 72, 269-278 [Medline] [Order article via Infotrieve]
  21. Williams, J. H., and Bliss, T. V. P. (1989) Neurosci. Lett. 107, 301-306 [CrossRef][Medline] [Order article via Infotrieve]
  22. Kato, K., Clark, G. D., Bazan, N. G., and Zorumski, C. F. (1994) Nature 367, 175-179 [CrossRef][Medline] [Order article via Infotrieve]
  23. Matsubara, M., Kusubata, M., Ishiguro, K., Uchida, T., Titani, K., and Taniguchi, H. (1996) J. Biol. Chem. 271, 21108-21113 [Abstract/Free Full Text]
  24. Brugg, B., and Matus, A. (1991) J. Cell Biol. 114, 735-743 [Abstract]
  25. Roberts, T. M. (1992) Science 360, 534-535
  26. Xing, J., Ginty, D. D., and Greenberg, M. E. (1996) Science 273, 959-963 [Abstract]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.